1
|
Zeng H, Zhou J, Huang C, Zhu Q. Clinical application of the modified Pullicino formula in endovascular thrombectomy in acute anterior circulation large cerebral infarction-A two-center retrospective study. J Stroke Cerebrovasc Dis 2025; 34:108137. [PMID: 39547550 DOI: 10.1016/j.jstrokecerebrovasdis.2024.108137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 10/10/2024] [Accepted: 11/11/2024] [Indexed: 11/17/2024] Open
Abstract
AIMS This study aimed to assess whether the modified Pullicino formula could be used as a screening indicator for measuring infarct volume before endovascular thrombectomy (EVT) and observe baseline factors affecting neurological recovery in patients with acute anterior circulation large-core cerebral infarction. METHODS The Pullicino formula × (1-22 %) was applied to anterior circulation large cerebral infarctions with ASPECTS <6 to screen patients with infarct volumes of 70-150 mL. The outcomes were assessed by mRS score at 90 days, modified Treatment in Cerebral Ischemia (mTICI) score, symptomatic intracranial hemorrhage within 48 h, and death rate within 90 days. RESULTS Significantly more patients in the EVT group with infarct volumes 70-150 mL had mRS ≤ 3 at 90 days than did the standard drug therapy (OR, 2.93; 95 % CI, 1.08-7.89, p = 0.03) and a significantly decreased mortality rate (OR, 0.36; 95 % CI, 0.13-0.98; p = 0.04), with 88.2 % in patients with mTICI ≥ 2b. There was no significant difference in the intracranial hemorrhage. EVT (adjusted OR [aOR], 2.84; 95 % CI, 1.15-7.01, p = 0.02), infarct volume <150 mL (aOR, 3.47; 95 % CI, 1.20-10.14, p = 0.02), and intracranial atherosclerosis (aOR, 4.20; 95 % CI, 1.24-14.04, p = 0.02) were significantly associated with patient prognosis. CONCLUSIONS Without commercial artificial intelligence software, the modified Pullicino formula can be used to calculate infarct volume and, in combination with ASPECTS <6, to select patients who may benefit from EVT.
Collapse
Affiliation(s)
- Hai Zeng
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
| | - Jia Zhou
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
| | - Chenyang Huang
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
| | - Qingfeng Zhu
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
| |
Collapse
|
2
|
Zhou J, Huang C, Zeng H. Use of cerebral hemorrhage volume calculation methods in patients with ASPECTS <6. Heliyon 2024; 10:e40421. [PMID: 39634407 PMCID: PMC11616561 DOI: 10.1016/j.heliyon.2024.e40421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 09/23/2024] [Accepted: 11/13/2024] [Indexed: 12/07/2024] Open
Abstract
Objective We aimed to determine whether the ABC/2 can be used as an infarct volume measurement tool for Mechanical thrombectomy (MT) in patients with Alberta Stroke Program Early CT Scores (ASPECTS) < 6. Methods Patients with stroke with ASPECTS <6 within 24 h were included in this study, and infarct volume was measured using the ABC/2. The patients were categorized into MT and standard drug groups. They were assessed based on a modified Rankin Scale (mRS) ≤3 at 3 months, intracranial hemorrhage within 48 h, and mortality at 3 months. Results ASPECTS <6 showed a significant negative correlation with infarct volume measured using the ABC/2. Compared to drug therapy, the patients who received MT treatment had a higher proportion of achieving an mRS score of ≤3 (OR, 2.60; 95 % confidence interval [CI], 1.04-6.50; P = 0.040), a lower death rate (OR, 0.37; 95 % CI, 0.15-0.92; P = 0.031), and a reduced decompressive craniectomy (OR, 0.10; 95 % CI, 0.01-0.83; P = 0.033); however, intracranial hemorrhage risk significantly increased (OR, 4.35; 95 % CI, 1.12-17.0; P = 0.034). Conclusion In the absence of advanced imaging, the ABC/2 can be a useful tool for measuring volume in anterior circulation in patients with ASPECTS <6.
Collapse
Affiliation(s)
- Jia Zhou
- Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, 030001, China
| | - Chenyang Huang
- Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, 030001, China
| | - Hai Zeng
- Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, 030001, China
| |
Collapse
|
3
|
Zeng H, Zhou J, Xue Q, Zhao F, Liu T, Zhu Q. Clinical Observation of Infarct Volume ≥150 mL in Endovascular Thrombectomy Treatment. Neurologist 2024; 29:311-316. [PMID: 38888296 DOI: 10.1097/nrl.0000000000000574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/20/2024]
Abstract
OBJECTIVES Whether patients with infarct volume ≥150 mL could benefit from endovascular thrombectomy (EVT) remains unclear. METHODS Patients (n=104) with anterior circulation Alberta Stroke Program Early Computed Tomography Score <6 were screened for infarct volume ≥150 mL using the Pullicino formula × (1-22%). The following were compared with the baseline at 90 days: the modified Rankin scale score (mRS) ≤3, mortality rate, symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and modified Thrombolysis in Cerebral Infarction (mTICI) ≥2b between the EVT and drug therapy (DT) groups. RESULTS In patients with infarct volumes ≥150 mL, mRS≤3 at 90 days was higher in the EVT group than in the DT group [adjusted odds risk (aOR), 5.52; 95% CI: 1.10-28.24, P =0.04), and mTICI ≥2b at 82.8%. Intracranial hemorrhage within 48 hours occurred in 7 (24.1%) patients in the EVT group and 5 (14.7%) in the DT group (aOR, 0.75; 95% CI: 0.16-3.46; P =0.71). Older age (aOR, 0.94; 95% CI: 0.90-0.99, P =0.01), EVT treatment (aOR, 4.51; 95% CI: 1.60-12.78, P =0.01), and infarct volume ≥150 mL (aOR, 0.11; 95% CI: 0.04-0.31, P <0.01) were significantly associated with patient prognosis. CONCLUSIONS Patients with infarct volume ≥150 mL who received EVT had a higher proportion of mRS≤3 compared with those who received DT. However, there was no statistically significant difference in intracranial hemorrhage and death between the groups. EVT, smaller infarct volume, and younger age were associated with a good prognosis. The findings require large sample data verification.
Collapse
Affiliation(s)
- Hai Zeng
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan
| | - Jia Zhou
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan
| | - Qing Xue
- Department of Neurology, Yuncheng Central Hospital, Shanxi Province, Yuncheng, China
| | - Fengli Zhao
- Department of Neurology, Yuncheng Central Hospital, Shanxi Province, Yuncheng, China
| | - Tingyu Liu
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan
| | - Qingfeng Zhu
- Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan
| |
Collapse
|
4
|
Safouris A, Palaiodimou L, Szikora I, Kargiotis O, Magoufis G, Psychogios K, Paraskevas G, Spiliopoulos S, Brountzos E, Nardai S, Goyal N, De Sousa DA, Strbian D, Caso V, Alexandrov A, Tsivgoulis G. Endovascular treatment for anterior circulation large-vessel occlusion ischemic stroke with low ASPECTS: a systematic review and meta-analysis. Ther Adv Neurol Disord 2022; 15:17562864221139632. [PMID: 36467113 PMCID: PMC9716457 DOI: 10.1177/17562864221139632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Accepted: 10/31/2022] [Indexed: 08/30/2023] Open
Abstract
Background Endovascular treatment (EVT) for acute ischemic stroke (AIS) patients presenting with Alberta Stroke Program Early CT Score (ASPECTS) 0-5 has not yet proven safe and effective by clinical trials. Objectives The aim of the study was to assess whether EVT in AIS patients presenting with low ASPECTS is beneficial. Design Systematic review and meta-analysis of available studies in accordance with the PRISMA statement. Data sources and Methods We have searched MEDLINE, the Cochrane Central Register of Controlled Trials, and reference lists of articles published until 28 May 2022 with the aim to calculate (1) modified Rankin scale (mRS) score 0-3 at 3 months, (2) mRS score 0-2 at 3 months, (3) symptomatic intracranial hemorrhage (sICH), and (3) mortality at 3 months. Results Overall, 24 eligible studies were included in the meta-analysis, comprising a total of 2539 AIS patients with ASPECTS 0-5 treated with EVT. The pooled proportion of EVT-treated patients achieving mRS 0-3 at 3 months was calculated at 38.4%. The pooled proportion of EVT-treated patients achieving mRS 0-2 at 3 months was 25.7%. Regarding safety outcomes, sICH occurred in 12.8% of patients. The 3-month pooled mortality was 30%. In pairwise meta-analysis, patients treated with EVT had a higher likelihood of achieving mRS 0-3 at 3 months compared with patients treated with best medical therapy (BMT, OR: 2.41). sICH occurred more frequently in EVT-treated patients compared with the BMT-treated patients (OR: 2.30). Mortality at 3 months was not different between the two treatment groups (OR: 0.71). Conclusion EVT may be beneficial for AIS patients with low baseline ASPECTS despite an increased risk for sICH. Further data from randomized-controlled clinical trials are needed to elucidate the role of EVT in this subgroup of AIS patients. Registration The protocol has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO; Registration Number: CRD42022334417.
Collapse
Affiliation(s)
- Apostolos Safouris
- Stroke Unit, Metropolitan Hospital, Piraeus,
Greece
- Second Department of Neurology, Attikon
University Hospital, Athens, Greece
- School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece
- Aktios Rehabilitation Center, Athens,
Greece
- Department of Neurointerventions, National
Institute of Mental Health, Neurology and Neurosurgery, Section of
Neurointervention, Department of Neurosurgery, Semmelweis University,
Budapest, Hungary
| | - Lina Palaiodimou
- Second Department of Neurology, Attikon
University Hospital, Athens, Greece
- School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece
| | - István Szikora
- Department of Neurointerventions, National
Institute of Mental Health, Neurology and Neurosurgery, Section of
Neurointervention, Department of Neurosurgery, Semmelweis University,
Budapest, Hungary
| | | | - George Magoufis
- Neuroradiology Department, Metropolitan
Hospital, Piraeus, Greece
| | | | - Georgios Paraskevas
- Second Department of Neurology, Attikon
University Hospital, Athens, Greece
- School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece
| | - Stavros Spiliopoulos
- Interventional Radiology Department, Attikon
University Hospital, Athens, Greece
| | - Elias Brountzos
- Interventional Radiology Department, Attikon
University Hospital, Athens, Greece
| | - Sándor Nardai
- Department of Neurointerventions, National
Institute of Mental Health, Neurology and Neurosurgery, Section of
Neurointervention, Department of Neurosurgery, Semmelweis University,
Budapest, Hungary
| | - Nitin Goyal
- Department of Neurology, The University of
Tennessee Health Science Center, Memphis, TN, USA
- Department of Neurosurgery, The University of
Tennessee Health Science Center and Semmes Murphey Neurologic and Spine
Clinic. Memphis, TN, USA
| | - Diana Aguiar De Sousa
- Stroke Center, Lisbon Central University
Hospital and Faculty of Medicine, University of Lisbon, Lisbon,
Portugal
| | - Daniel Strbian
- Neurological Research Unit, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
| | - Valeria Caso
- Neurology Unit, ‘M. Bufalini’ Hospital-AUSL
Romagna, Cesena, Italy
| | - Andrei Alexandrov
- Department of Neurology, The University of
Tennessee Health Science Center, Memphis, TN, USA
| | - Georgios Tsivgoulis
- Second Department of Neurology, Attikon
University Hospital, Rimini 1, Chaidari, 124 62 Athens, Greece
- School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece
- Department of Neurology, The University of
Tennessee Health Science Center, Memphis, TN, USA
| |
Collapse
|
5
|
Bing F, Berger I, Fabry A, Moroni AL, Casile C, Morel N, M'Biene S, Guellerin J, Pignal-Jacquard C, Vadot W, Rodier G, Delory T, Jund J. Intra- and inter-rater consistency of dual assessment by radiologist and neurologist for evaluating DWI-ASPECTS in ischemic stroke. Rev Neurol (Paris) 2021; 178:219-225. [PMID: 34785042 DOI: 10.1016/j.neurol.2021.08.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 08/04/2021] [Accepted: 08/11/2021] [Indexed: 11/15/2022]
Abstract
OBJECTIVES To estimate the intra -and inter-rater consistency of radiologist and neurologist working in pairs attributing DWI-ASPECTS (Diffusion Alberta Stroke Program Early CT Score) in patients with acute middle cerebral artery ischemic stroke referred for mechanical thrombectomy, intravenous thrombolysis or bridging therapy. METHODS Five neurologists and 5 radiologists working in pairs and in hour period scored independently and in two reading sessions anonymized DWI-ASPECTS of 80 patients presenting with acute anterior ischaemic stroke in our center. We measured agreement between pairs using intraclass correlation coefficients (ICCs). A Fleiss kappa was used for dichotomized (0-6;7-10) and trichotomized (0-3;4-6;7-10) ASPECTS. The interrater distribution of the score in the trichotomized (0-3;4-6;7-10) ASPECTS was calculated. We determined the interrater (Cohen kappa) and intrarater (Fleiss kappa) agreement on the ASPECTS regions. RESULTS The average DWI-ASPECTS was 6.35 (SD±2.44) for the first reading, and 6.47 (SD±2.44) for the second one. The ICC was 0.853 (95%CI, 0.798-0.896) for the interrater, and 0.862 (95%CI, 0.834-0.885) for the intrarater evaluation. Kappa coefficients were high for dichotomized (k=0.75) and trichotomized (k=0.64) ASPECTS. Evaluators agreement on the ASPECTS category (0-3), (4-6) and (7-10) was 88, 76 and 93% respectively. The anatomic region infarcted was well identified (k=0.70-0.77), except for the internal capsula (k=0.57). Interrater agreement was fair for M5 (k=0.37), moderate for internal capsula (0.52) and substantial for the other regions (0.60-0.79). CONCLUSIONS Reliability of DWI-ASPECTS is good when determined by radiologist and neurologist working in pairs, which corresponds to our current clinical practice. However, discrepancies are possible for cut-off determination, which may impact the indication of thrombectomy, and for the determination of the exact infarcted region. Agreement to propose category (4-6) is lower than for (0-3) and (8-10) ASPECTS categories.
Collapse
Affiliation(s)
- F Bing
- Radiology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France.
| | - I Berger
- Neurology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - A Fabry
- Radiology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - A-L Moroni
- Radiology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - C Casile
- Radiology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - N Morel
- Neurology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - S M'Biene
- Radiology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - J Guellerin
- Neurology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - C Pignal-Jacquard
- Radiology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - W Vadot
- Neurology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - G Rodier
- Neurology Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - T Delory
- Clinical Research Unit, CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| | - J Jund
- Medical Information and Evaluation Unit (SIEM), CHANGE, 1, avenue de l'Hôpital, 74370 Metz-Tessy, France
| |
Collapse
|
6
|
Bouslama M, Barreira CM, Haussen DC, Rodrigues GM, Pisani L, Frankel MR, Nogueira RG. Endovascular reperfusion outcomes in patients with a stroke and low ASPECTS is highly dependent on baseline infarct volumes. J Neurointerv Surg 2021; 14:117-121. [PMID: 33722970 DOI: 10.1136/neurintsurg-2020-017184] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Revised: 02/12/2021] [Accepted: 02/13/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND Patients with large vessel occlusion stroke (LVOS) and a low Alberta Stroke Program Early CT Score (ASPECTS) are often not offered endovascular therapy (ET) as they are thought to have a poor prognosis. OBJECTIVE To compare the outcomes of patients with low and high ASPECTS undergoing ET based on baseline infarct volumes. METHODS Review of a prospectively collected endovascular database at a tertiary care center between September 2010 and March 2020. All patients with anterior circulation LVOS and interpretable baseline CT perfusion (CTP) were included. Subjects were divided into groups with low ASPECTS (0-5) and high ASPECTS (6-10) and subsequently into limited and large CTP-core volumes (cerebral blood flow 30% >70 cc). The primary outcome measure was the difference in rates of 90-day good outcome as defined by a modified Rankin Scale (mRS) score of 0 to 2 across groups. RESULTS 1248 patients fit the inclusion criteria. 125 patients had low ASPECTS, of whom 16 (12.8%) had a large core (LC), whereas 1123 patients presented with high ASPECTS, including 29 (2.6%) patients with a LC. In the category with a low ASPECTS, there was a trend towards lower rates of functional independence (90-day modified Rankin Scale (mRS) score 0-2) in the LC group (18.8% vs 38.9%, p=0.12), which became significant after adjusting for potential confounders in multivariable analysis (aOR=0.12, 95% CI 0.016 to 0.912, p=0.04). Likewise, LC was associated with significantly lower rates of functional independence (31% vs 51.9%, p=0.03; aOR=0.293, 95% CI 0.095 to 0.909, p=0.04) among patients with high ASPECTS. CONCLUSIONS Outcomes may vary significantly in the same ASPECTS category depending on infarct volume. Patients with ASPECTS ≤5 but baseline infarct volumes ≤70 cc may achieve independence in nearly 40% of the cases and thus should not be excluded from treatment.
Collapse
Affiliation(s)
- Mehdi Bouslama
- Department of Neurology, Emory University, Atlanta, Georgia, USA
| | - Clara M Barreira
- Department of Neurology, Neurosurgery and Radiology, Emory University, Atlanta, Georgia, USA
| | - Diogo C Haussen
- Department of Neurology, Neurosurgery and Radiology, Emory University, Atlanta, Georgia, USA
| | | | - Leonardo Pisani
- Department of Radiology, Georgetown University Medical Center, Washington, District of Columbia, USA
| | | | - Raul G Nogueira
- Department of Neurology and Interventional Neuroradiology, Emory University, Atlanta, Georgia, USA
| |
Collapse
|
7
|
Chang YM, Tenenbaum M, Xiong Y, Selim M, Bhadelia R, Hacein-Bey L, Ivanovic V. Brain Computed Tomography Angiography Maximum Intensity Projection Images for ASPECTS Derivation and Detection of Large Infarct Volumes: Preliminary Study. J Stroke Cerebrovasc Dis 2020; 30:105548. [PMID: 33360519 DOI: 10.1016/j.jstrokecerebrovasdis.2020.105548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 12/01/2020] [Accepted: 12/07/2020] [Indexed: 10/22/2022] Open
Abstract
PURPOSE Non-contrast CT ASPECTS (NCCTasp) has an established role in determining eligibility for mechanical thrombectomy in centers without ready access to perfusion or DWI. Moreover, it has been suggested that CTA source ASPECTS (CTAasp) may be superior to NCCTasp in predicting final infarct volume (FIV). In this study, we hypothesized that CTA maximum intensity projection ASPECTS (MIPSasp) would be superior compared to both NCCTasp and CTAasp in predicting FIV as measured by DWI. MATERIALS AND METHODS In 41 consecutive patients with MCA territory infarcts, NCCTasp, CTAasp and MIPSasp were visually assessed by 2 neuroradiologists. Disagreements were adjudicated by a third neuroradiologist, and the reconciled data used for all further analysis. MR-DWI was used as the standard for FIV determination. Receiver operating characteristic curve analysis was used to compare the area under the curve for all three CT-based methods in predicting FIV ≥70 ml. RESULTS MIPSasp (AUC: 0.98, CI: 0.88-1.00) were statistically better than NCCTasp (AUC: 0.87, 95% CI: 0.72-0.95; p=0.01) in predicting FIV ≥70 ml. MIPSasp were also superior to CTAasp (AUC: 0.9, CI: 0.79-.98; p˂0.05). Optimal test performance for predicting FIV ≥70 ml for MIPSasp was ≤6 (sensitivity=100%, specificity=91.4%; Youden's J=0.98). CONCLUSION Our preliminary study suggests that a novel CTA-MIPS derived ASPECTS better predicts large MCA territory infarcts compared to CTA source and non-contrast ASPECTS. Thus, MIPSasp may be a promising technique for future studies aimed at improving ischemic stroke treatment in centers using ASPECTS for stroke management.
Collapse
Affiliation(s)
- Yu-Ming Chang
- Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States.
| | | | - Yunyun Xiong
- Beijing Tiantan Hospital, China; Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States
| | - Magdy Selim
- Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States
| | - Rafeeque Bhadelia
- Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States
| | - Lotfi Hacein-Bey
- Davis School of Medicine, University of California, United States
| | | |
Collapse
|
8
|
Xu K, Gu B, Zuo T, Xu X, Chen YC, Yin X, Feng G. Predictive value of Alberta stroke program early CT score for perfusion weighted imaging - diffusion weighted imaging mismatch in stroke with middle cerebral artery occlusion. Medicine (Baltimore) 2020; 99:e23490. [PMID: 33327283 PMCID: PMC7738142 DOI: 10.1097/md.0000000000023490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
This study aimed to quantitatively assess the consistency and correlation between perfusion weighted imaging (PWI)/ diffusion weighted imaging (DWI) Alberta Stroke Program Early CT Score (ASPECTS) mismatch and PWI/DWI mismatch.Sixty-eight acute ischemic stroke with middle cerebral artery occlusion who underwent magnetic resonance imaging before thrombectomy were eligible. DWI volume, PWI volume and PWI-DWI mismatch were measured. DWI-, PWI-, PWI-DWI ASPECTS were evaluated. Statistical analysis was performed to compare the correlation between volume and ASPECTS of DWI-, PWI- and PWI-DWI mismatch. Receiver operating characteristic curve analysis was used to assess the predictive value of the PWI-DWI ASPECTS mismatch for the occurrence of PWI-DWI mismatch in acute ischemic stroke patients with middle cerebral artery occlusion.Of 68 patients, the DWI volume, PWI volume and PWI-DWI mismatch volume were (27.76 ± 17.53) mL, (167.09 ± 59.64) mL and (139.33 ± 58.18) mL respectively. DWI-ASPECTS was 6.75 ± 1.90 with the interobserver agreement was κ=0.98 (95% CI, 0.95-0.99); PWI-ASPECTS was 3.09 ± 2.11 with the interobserver agreement was κ=0.95 (95% CI, 0.91-0.99); PWI-DWI ASPECTS mismatch was 6.75 ± 1.90. Spearman's rank correlation analysis revealed that PWI-DWI mismatch volume was negatively correlated with PWI-DWI ASPECTS mismatch (r = -0.802; P = .000). Receiver operating characteristic analysis showed that when the PWI-DWI ASPECTS mismatch cut point was ≥ 2, the under curve of PWI-DWI ASPECTS mismatch for predicting PWI-DWI mismatch was 0.954 (95%CI, 0.911-0.998), with the sensitivity and specificity were 84.00% and 100% respectively.PWI-DWI ASPECTS mismatch may represent a convenient surrogate for penumbra in clinical trials.
Collapse
Affiliation(s)
| | - Baodong Gu
- Department of Neurology, Affiliated Lianyungang Traditional Chinese Medicine Hospital of Kangda College of Nanjing Medical University, Lianyungang
| | | | | | - Yu-Chen Chen
- Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Xindao Yin
- Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Guangkui Feng
- Department of Neurology, Affiliated Lianyungang Traditional Chinese Medicine Hospital of Kangda College of Nanjing Medical University, Lianyungang
| |
Collapse
|
9
|
Affiliation(s)
- Raul G. Nogueira
- From the Department of Neurology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA (R.G.N.)
| | - Marc Ribó
- Department of Neurology, Hospital Vall d’Hebron, Barcelona, Spain (M.R.)
| |
Collapse
|
10
|
Freyschlag CF, Boehme C, Bauer M, Kerschbaumer J, Pinggera D, Riedmann M, Unterhofer C, Grams AE, Knoflach M, Thomé C. The Volume of Ischemic Brain Predicts Poor Outcome in Patients with Surgically Treated Malignant Stroke. World Neurosurg 2019; 123:e515-e519. [DOI: 10.1016/j.wneu.2018.11.197] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 11/20/2018] [Accepted: 11/21/2018] [Indexed: 10/27/2022]
|
11
|
Abstract
The Alberta Stroke Program Early CT score (ASPECTS) is a 10-point semiquantitative topographic scoring system developed for the assessment of early ischemic changes (EICs) on noncontrast-enhanced computed tomography (NCCT) in patients with acute ischemic stroke involving the middle cerebral artery (MCA) territory. One point is subtracted from a total score of 10, if an EIC is present in any part of each of the ASPECTS regions. Higher ASPECTS has been associated with better outcomes and a lower risk of symptomatic intracerebral hemorrhage. To date, there are still controversies regarding the utility of ASPECTS for selecting patients for intravenous and intra-arterial therapies. This article provides a comprehensive review regarding methodology, limitations, and interobserver reproducibility of ASPECTS, as well as application of ASPECTS in clinical care. The focus of this review is ASPECTS evaluation on NCCT. The application of ASPECTS on multimodal computed tomography and magnetic resonance imaging (MRI) is briefly described.
Collapse
Affiliation(s)
- Supada Prakkamakul
- *Department of Radiology, King Chulalongkorn Memorial Hospital the Thai Red Cross Society, Bangkok, Thailand †Division of Neurointervention, Texas Stroke Institute, Plano, TX
| | | |
Collapse
|
12
|
Schröder J, Thomalla G. A Critical Review of Alberta Stroke Program Early CT Score for Evaluation of Acute Stroke Imaging. Front Neurol 2017; 7:245. [PMID: 28127292 PMCID: PMC5226934 DOI: 10.3389/fneur.2016.00245] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 12/29/2016] [Indexed: 01/19/2023] Open
Abstract
Assessment of ischemic stroke lesions on computed tomography (CT) or MRI using the Alberta Stroke Program Early CT Score (ASPECTS) is widely used to guide acute stroke treatment. We aimed to review the current evidence on ASPECTS. Originally, the score was developed for standardized lesion assessment on non-contrast CT (NCCT). Early studies described ASPECTS as a predictor of functional outcome and symptomatic intracranial hemorrhage after iv-thrombolysis with a threshold of ≤7 suggested to identify patients at high risk. Following studies rather pointed toward a linear relationship between ASPECTS and functional outcome. ASPECTS has also been applied to assess perfusion CT and diffusion-weighted MRI (DWI). Cerebral blood volume ASPECTS proved to be the best predictor of outcome, outperforming NCCT-ASPECTS in some studies. For DWI-ASPECTS varying thresholds to identify patients at risk for poor outcome were reported. ASPECTS has been used for patient selection in three of the five groundbreaking trials proving efficacy of mechanical thrombectomy published in 2015. ASPECTS values predict functional outcome after thrombectomy. Moreover, treatment effect of thrombectomy appears to depend on ASPECTS values being smaller or not present in low ASPECTS, while patients with ASPECTS 5–10 do clearly benefit from mechanical thrombectomy. However, as patients with low ASPECTS values were excluded from recent trials data on this subgroup is limited. There are several limitations to ASPECTS addressed in a growing number of studies. The score is limited to the anterior circulation, the template is unequally weighed and correlation with lesion volume depends on lesion location. Overall ASPECTS is a useful and easily applicable tool for assessment of prognosis in acute stroke treatment and to help guide acute treatment decisions regardless whether MRI or CT is used. Patients with low ASPECTS values are unlikely to achieve good outcome. However, methodological constraints of ASPECTS have to be considered, and based on present data, a clear cutoff value to define “low ASPECTS values” cannot be given.
Collapse
Affiliation(s)
- Julian Schröder
- Department of Neurology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| | - Götz Thomalla
- Department of Neurology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany
| |
Collapse
|
13
|
Lassalle L, Turc G, Tisserand M, Charron S, Roca P, Lion S, Legrand L, Edjlali M, Naggara O, Meder JF, Mas JL, Baron JC, Oppenheim C. ASPECTS (Alberta Stroke Program Early CT Score) Assessment of the Perfusion-Diffusion Mismatch. Stroke 2016; 47:2553-8. [PMID: 27625381 DOI: 10.1161/strokeaha.116.013676] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 08/05/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Rapid and reliable assessment of the perfusion-weighted imaging (PWI)/diffusion-weighted imaging (DWI) mismatch is required to promote its wider application in both acute stroke clinical routine and trials. We tested whether an evaluation based on the Alberta Stroke Program Early CT Score (ASPECTS) reliably identifies the PWI/DWI mismatch. METHODS A total of 232 consecutive patients with acute middle cerebral artery stroke who underwent pretreatment magnetic resonance imaging (PWI and DWI) were retrospectively evaluated. PWI-ASPECTS and DWI-ASPECTS were determined blind from manually segmented PWI and DWI volumes. Mismatch-ASPECTS was defined as the difference between PWI-ASPECTS and DWI-ASPECTS (a high score indicates a large mismatch). We determined the mismatch-ASPECTS cutoff that best identified the volumetric mismatch, defined as VolumeTmax>6s/VolumeDWI≥1.8, a volume difference≥15 mL, and a VolumeDWI<70 mL. RESULTS Inter-reader agreement was almost perfect for PWI-ASPECTS (κ=0.95 [95% confidence interval, 0.90-1]), and DWI-ASPECTS (κ=0.96 [95% confidence interval, 0.91-1]). There were strong negative correlations between volumetric and ASPECTS-based assessments of DWI lesions (ρ=-0.84, P<0.01) and PWI lesions (ρ=-0.90, P<0.01). Receiver operating characteristic curve analysis showed that a mismatch-ASPECTS ≥2 best identified a volumetric mismatch, with a sensitivity of 0.93 (95% confidence interval, 0.89-0.98) and a specificity of 0.82 (95% confidence interval, 0.74-0.89). CONCLUSIONS The mismatch-ASPECTS method can detect a true mismatch in patients with acute middle cerebral artery stroke. It could be used for rapid screening of patients with eligible mismatch, in centers not equipped with ultrafast postprocessing software.
Collapse
Affiliation(s)
- Louis Lassalle
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Guillaume Turc
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Marie Tisserand
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Sylvain Charron
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Pauline Roca
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Stephanie Lion
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Laurence Legrand
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Myriam Edjlali
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Olivier Naggara
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Jean-François Meder
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Jean-Louis Mas
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Jean-Claude Baron
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
| | - Catherine Oppenheim
- From the Departments of Radiology (L. Lassalle, M.T., S.C., P.R., S.L., L. Legrand, M.E., O.N., J.-F.M., C.O.), and Neurology (G.T., J.-L.M., J.-C.B.), Université Paris Descartes Sorbonne Paris Cité, Centre de Psychiatrie et Neurosciences, INSERM S894, DHU Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France.
| |
Collapse
|
14
|
Kim SK, Yoon W, Park MS, Heo TW, Baek BH, Lee YY. Outcomes Are Not Different between Patients with Intermediate and High DWI-ASPECTS after Stent-Retriever Embolectomy for Acute Anterior Circulation Stroke. AJNR Am J Neuroradiol 2016; 37:1080-5. [PMID: 26767711 DOI: 10.3174/ajnr.a4663] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 11/23/2015] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Questions remain as to what benefits embolectomy provides to patients presented with considerable early ischemic changes on baseline imaging studies. This study aimed to investigate the impact of the Alberta Stroke Program Early CT Score applied to DWI on treatment outcomes in patients with acute stroke undergoing stent-retriever embolectomy. MATERIALS AND METHODS We retrospectively analyzed the clinical and DWI data from 171 patients with acute anterior circulation stroke who were treated with stent-retriever embolectomy within 6 hours of symptom onset. DWI-ASPECTS scores were analyzed with the full scale or were dichotomized (4-6 versus 7-10). Patients with DWI-ASPECTS ≤3 were excluded from the study. Associations between outcome and clinical and radiologic factors were determined with a multivariate logistic regression analysis. A good outcome was defined as a modified Rankin Scale score of 0-2 at 3 months. RESULTS The median DWI-ASPECTS was 7 (interquartile range, 6-8). The rates of good outcome, symptomatic hemorrhage, and mortality were not different between high DWI-ASPECTS (scores of 7-10) and intermediate DWI-ASPECTS (scores of 4-6) groups. In patients with an intermediate DWI-ASPECTS, good outcome was achieved in 46.5% (20/43) of patients with successful revascularization, whereas no patients without successful revascularization had a good outcome (P = .016). In multivariate logistic regression analysis, independent predictors of good outcome were age and successful revascularization. CONCLUSIONS Our study suggested that there were no differences in outcomes between patients with a high DWI-ASPECTS and those with an intermediate DWI-ASPECTS who underwent stent-retriever embolectomy for acute anterior circulation stroke. Thus, patients with an intermediate DWI-ASPECTS otherwise eligible for endovascular therapy may not be excluded from stent-retriever embolectomy or stroke trials.
Collapse
Affiliation(s)
- S K Kim
- From the Departments of Radiology (S.K.K., W.Y., T.W.H., B.H.B., Y.Y.L.)
| | - W Yoon
- From the Departments of Radiology (S.K.K., W.Y., T.W.H., B.H.B., Y.Y.L.)
| | - M S Park
- Neurology (M.S.P.), Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Republic of Korea
| | - T W Heo
- From the Departments of Radiology (S.K.K., W.Y., T.W.H., B.H.B., Y.Y.L.)
| | - B H Baek
- From the Departments of Radiology (S.K.K., W.Y., T.W.H., B.H.B., Y.Y.L.)
| | - Y Y Lee
- From the Departments of Radiology (S.K.K., W.Y., T.W.H., B.H.B., Y.Y.L.)
| |
Collapse
|
15
|
Bae YJ, Jung C, Kim JH, Choi BS, Kim E. Quantitative Magnetic Resonance Angiography in Internal Carotid Artery Occlusion with Primary Collateral Pathway. J Stroke 2015; 17:320-6. [PMID: 26437997 PMCID: PMC4635716 DOI: 10.5853/jos.2015.17.3.320] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 08/17/2015] [Accepted: 08/25/2015] [Indexed: 11/27/2022] Open
Abstract
Background and Purpose Quantitative magnetic resonance angiography (Q-MRA) enables direct measurement of volume flow rate (VFR) of intracranial arteries. We aimed to evaluate the collateral flows in internal carotid artery (ICA) occlusion with primary collateral pathway via circle of Willis using Q-MRA, and to compare them between patients who recently developed ipsilateral symptomatic ischemia and those who did not. Methods Between 2012 and 2014, 505 patients underwent Q-MRA in our institution. Among these, 33 patients who had unilateral ICA occlusion with primary collateral pathway were identified, and grouped into asymptomatic patients, stable patients with chronic infarction, and symptomatic patients with acute/subacute infarction. Mean VFR (mVFR) in intracranial arteries was measured and compared between the patients’ groups. Kruskal-Wallis test was used for statistical analysis. Results Six patients were asymptomatic, fifteen with chronic infarction were stable, and twelve with acute/subacute infarction were symptomatic. The mVFR of ipsilateral middle cerebral artery in symptomatic patients was significantly lower than those in stable or asymptomatic patients (73.7±45.6 mL/min vs. 119.9±36.1 mL/min vs. 121.8±42.0 mL/min; P = 0.04). Total sum of the mVFR of ipsilateral anterior, middle, and posterior cerebral arteries was significantly lower in symptomatic patients than those in other groups (229.3 ± 51.3 mL/min vs. 282.0±68.6 mL/min vs. 314.0±44.4 mL/min; P = 0.02). Conclusions Q-MRA could be helpful to demonstrate the difference in the degree of primary collateral flow in ICA occlusion between the patients with recent symptomatic ischemia and those without.
Collapse
Affiliation(s)
- Yun Jung Bae
- Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
| | - Cheolkyu Jung
- Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
| | - Jae Hyoung Kim
- Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
| | - Byung Se Choi
- Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
| | - Eunhee Kim
- Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea ; Department of Radiology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
| |
Collapse
|
16
|
Ibatullin MM, Kalinin MN, Curado AT, Khasanova DR. [Neurovisualisation predictors of malignant cerebral infarction and hemorrhagic transformation]. Zh Nevrol Psikhiatr Im S S Korsakova 2015; 115:3-11. [PMID: 26120991 DOI: 10.17116/jnevro2015115323-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Neuroimaging plays a central role in the assessment of patients with acute ischemic stroke. Within a few minutes, modern multimodal imaging protocols can provide one with comprehensive information about prognosis, management, and outcome of the disease, and may detect changes in the intracranial structures reflecting severity of the ischemic injury depicted by four Ps: parenchyma (of the brain), pipes (i.e., the cerebral blood vessels), penumbra, and permeability (of the blood brain barrier). In this article, we have reviewed neuroradiological predictors of malignant middle cerebral artery infarction and hemorrhagic transformation in light of the aforementioned four Ps.
Collapse
Affiliation(s)
| | | | - A T Curado
- Interregional Clinical Diagnostic Center, Kazan
| | | |
Collapse
|
17
|
McTaggart RA, Jovin TG, Lansberg MG, Mlynash M, Jayaraman MV, Choudhri OA, Inoue M, Marks MP, Albers GW. Alberta Stroke Program Early Computed Tomographic Scoring Performance in a Series of Patients Undergoing Computed Tomography and MRI. Stroke 2015; 46:407-12. [PMID: 25538199 DOI: 10.1161/strokeaha.114.006564] [Citation(s) in RCA: 111] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
In this study, we compare the performance of pretreatment Alberta Stroke Program Early Computed Tomographic scoring (ASPECTS) using noncontrast CT (NCCT) and MRI in a large endovascular therapy cohort.
Methods—
Prospectively enrolled patients underwent baseline NCCT and MRI and started endovascular therapy within 12 hours of stroke onset. Inclusion criteria for this analysis were evaluable pretreatment NCCT, diffusion-weighted MRI (DWI), and 90-day modified Rankin Scale scores. Two expert readers graded ischemic change on NCCT and DWI using the ASPECTS. ASPECTS scores were analyzed with the full scale or were trichotomized (0–4 versus 5–7 versus 8–10) or dichotomized (0–7 versus 8–10). Good functional outcome was defined as a 90-day modified Rankin Scale score of 0 to 2.
Results—
Seventy-four patients fulfilled our study criteria. The full-scale inter-rater agreement for CT-ASPECTS and DWI-ASPECTS was 0.579 and 0.867, respectively. DWI-ASPECTS correlated with functional outcome (
P
=0.004), whereas CT-ASPECTS did not (
P
=0.534). Both DWI-ASPECTS and CT-ASPECTS correlated with DWI volume. The receiver operating characteristic analysis revealed that DWI-ASPECTS outperformed both CT-ASPECTS and the time interval between symptom onset and start of the procedure for predicting good functional outcome (modified Rankin Scale score, ≤2) and DWI volume ≥70 mL.
Conclusion—
Inter-rater agreement for DWI-ASPECTS was superior to that for CT-ASPECTS. DWI-ASPECTS outperformed NCCT ASPECTS for predicting functional outcome at 90 days.
Collapse
Affiliation(s)
- Ryan A. McTaggart
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Tudor G. Jovin
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Maarten G. Lansberg
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Michael Mlynash
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Mahesh V. Jayaraman
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Omar A. Choudhri
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Manabu Inoue
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Michael P. Marks
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| | - Gregory W. Albers
- From the Department of Neurosurgery, Cleveland Clinic Florida, Weston (R.A.M.); Cerebrovascular Center, Cleveland Clinic, OH (R.A.M.); Department of Neurology, University of Pittsburgh School of Medicine, PA (T.G.J.); Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., M.M., O.A.C., M.I, M.P.M., G.W.A.); and Department of Diagnostic Imaging, Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, Providence (M.V.J.)
| |
Collapse
|
18
|
Aoki J, Tateishi Y, Cummings CL, Cheng-Ching E, Ruggieri P, Hussain MS, Uchino K. Collateral flow and brain changes on computed tomography angiography predict infarct volume on early diffusion-weighted imaging. J Stroke Cerebrovasc Dis 2014; 23:2845-2850. [PMID: 25440366 DOI: 10.1016/j.jstrokecerebrovasdis.2014.07.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2014] [Revised: 06/21/2014] [Accepted: 07/09/2014] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND We investigated whether a computed tomography (CT)-based score could predict a large infarct (≥ 80 mL) on early diffusion-weighted magnetic resonance imaging (DWI). METHODS Acute stroke patients considered for endovascular therapy within 8 hours of the onset of symptoms were included. The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) was determined on noncontrast CT and computed tomography angiography source images (CTA-SI). Limited collateral flow was defined as less than 50% collateral filling on CTA-SI. RESULTS Fifty-six patients were analyzed. National Institutes of Health Stroke Scale score was 20 (15-24) in the large infarct group and 16 (11-20) in the small infarct group (P = .049). ASPECTS on noncontrast CT and CTA-SI was 5 (3-8) and 3 (2-6) in the large infarct group and 9 (8-10) and 8 (7-9) in the small infarct group (both P < .001), respectively. Limited collateral flow was frequent in the large infarct group than in the small infarct group (92% vs. 11%, P < .001). Multivariate analysis found that CTA-SI ASPECTS less than or equal to 5 (odds ratio [OR], 40.55; 95% confidence interval [CI], 1.10-1493.44; P = .044) and limited collateral flow (OR, 114.64; 95% CI, 1.93-6812.79; P = .023) were associated with a large infarct. Absence of ASPECTS less than or equal to 5 and limited collateral flow on CTA-SI predicted absence of a large infarct with a sensitivity of .89, specificity of 1.00, positive predictive value of 1.00, and negative predictive value of .71. CONCLUSIONS Assessment of ASPECTS and collateral flow on CTA-SI may be able to exclude a patient with large infarct on early DWI.
Collapse
Affiliation(s)
- Junya Aoki
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
| | - Yohei Tateishi
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
| | | | - Esteban Cheng-Ching
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
| | - Paul Ruggieri
- Center for Neuroimaging, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
| | | | - Ken Uchino
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
| |
Collapse
|
19
|
Schröder J, Cheng B, Ebinger M, Köhrmann M, Wu O, Kang DW, Liebeskind DS, Tourdias T, Singer OC, Christensen S, Campbell B, Luby M, Warach S, Fiehler J, Fiebach JB, Gerloff C, Thomalla G. Validity of acute stroke lesion volume estimation by diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomographic Score depends on lesion location in 496 patients with middle cerebral artery stroke. Stroke 2014; 45:3583-8. [PMID: 25316278 DOI: 10.1161/strokeaha.114.006694] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) has been used to estimate diffusion-weighted imaging (DWI) lesion volume in acute stroke. We aimed to assess correlations of DWI-ASPECTS with lesion volume in different middle cerebral artery (MCA) subregions and reproduce existing ASPECTS thresholds of a malignant profile defined by lesion volume ≥100 mL. METHODS We analyzed data of patients with MCA stroke from a prospective observational study of DWI and fluid-attenuated inversion recovery in acute stroke. DWI-ASPECTS and lesion volume were calculated. The population was divided into subgroups based on lesion localization (superficial MCA territory, deep MCA territory, or both). Correlation of ASPECTS and infarct volume was calculated, and receiver-operating characteristics curve analysis was performed to identify the optimal ASPECTS threshold for ≥100-mL lesion volume. RESULTS A total of 496 patients were included. There was a significant negative correlation between ASPECTS and DWI lesion volume (r=-0.78; P<0.0001). With regards to lesion localization, correlation was weaker in deep MCA region (r=-0.19; P=0.038) when compared with superficial (r=-0.72; P<0.001) or combined superficial and deep MCA lesions (r=-0.72; P<0.001). Receiver-operating characteristics analysis revealed ASPECTS≤6 as best cutoff to identify ≥100-mL DWI lesion volume; however, positive predictive value was low (0.35). CONCLUSIONS ASPECTS has limitations when lesion location is not considered. Identification of patients with malignant profile by DWI-ASPECTS may be unreliable. ASPECTS may be a useful tool for the evaluation of noncontrast computed tomography. However, if MRI is used, ASPECTS seems dispensable because lesion volume can easily be quantified on DWI maps.
Collapse
Affiliation(s)
- Julian Schröder
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.).
| | - Bastian Cheng
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Martin Ebinger
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Martin Köhrmann
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Ona Wu
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Dong-Wha Kang
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - David S Liebeskind
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Thomas Tourdias
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Oliver C Singer
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Soren Christensen
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Bruce Campbell
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Marie Luby
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Steven Warach
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Jens Fiehler
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Jochen B Fiebach
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Christian Gerloff
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | - Götz Thomalla
- From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.S., B. Cheng, C.G., G.T.); Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany (M.E., J.B.F.); Klinik für Neurologie, Universität Erlangen-Nürnberg, Erlangen, Germany (M.K.); Department of Radiology, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston (O.W.); Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (D.-W.K.); Department of Neurology, University of California, Los Angeles (D.S.L.); Université de Bordeaux, CHU de Bordeaux, Service de NeuroImagerie Diagnostique de Thérapeutique, Bordeaux, France (T.T.); Klinik für Neurologie, Universitätsklinikum Frankfurt, Frankfurt, Germany (O.C.S.); Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (S.C., B. Campbell); National Institute of Neurological Disorders and Stroke, Bethesda, MD (M.L.); Department of Neurology and Neurotherapeutics, Seton/UT Southwestern Clinical Research Institute of Austin, UT Southwestern Medical Center, Austin, TX (S.W.); and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany (J.F.)
| | | |
Collapse
|
20
|
Inoue M, Olivot JM, Labreuche J, Mlynash M, Tai W, Albucher JF, Meseguer E, Amarenco P, Mazighi M. Impact of diffusion-weighted imaging Alberta stroke program early computed tomography score on the success of endovascular reperfusion therapy. Stroke 2014; 45:1992-8. [PMID: 24923724 DOI: 10.1161/strokeaha.114.005084] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE In acute ischemic stroke patients treated by intravenous thrombolysis, a diffusion-weighted imaging (DWI) Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is an independent factor of functional outcomes. Our aim was to assess the impact of pretreatment DWI-ASPECTS on outcomes after endovascular therapy, with a specific emphasis on recanalization. METHODS We analyzed data collected between April 2007 and March 2013 in a prospective clinical registry of acute ischemic stroke patients treated by endovascular approach. Every patient with a documented internal carotid artery or middle cerebral artery occlusion who underwent an acute DWI-MRI before treatment was eligible for this study. The primary outcome was a favorable outcome defined by modified Rankin Scale of 0 to 2 at 90 days. RESULTS Two hundred ten patients were included and median DWI-ASPECTS was 7 (interquartile range, 4-8). DWI-ASPECTS≥5 was the optimal threshold to predict a favorable outcome (area under the curve=0.69; sensitivity, 90%; specificity, 38%). In a multivariate analysis including confounding variables, the adjusted odds ratio for favorable outcomes associated with a DWI-ASPECTS of ≥5 was 5.06 (95% confidence interval, 1.86-13.77; P=0.002). Nonetheless, the occurrence of a complete recanalization was associated with an increased rate of favorable outcomes in patients with DWI-ASPECTS under 5 (50% versus 3%, P<0.001). CONCLUSIONS DWI-ASPECTS≥5 seems to be the optimal threshold to predict favorable outcomes among patients undergoing endovascular reperfusion within 6 hours. Selected patients with a DWI-ASPECTS of <5 may still benefit when a complete reperfusion is achieved.
Collapse
Affiliation(s)
- Manabu Inoue
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Jean-Marc Olivot
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Julien Labreuche
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Michael Mlynash
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Waimea Tai
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Jean-François Albucher
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Elena Meseguer
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Pierre Amarenco
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.)
| | - Mikael Mazighi
- From the Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, CA (M.I., J.-M.O., M. Mlynash); Department of Neurology, Purpan University Hospital, Toulouse, France (J.-M.O., J.-F.A.); Department of Neurology and Stroke Centre, Bichat University Hospital, APHP, Paris, France (E.M., P.A., M. Mazighi); INSERM U-1148, Laboratory of Vascular Translational Science and Paris-Diderot University, Paris, France (J.L., E.M., P.A., M. Mazighi); and Department of Biostatistics, EA2694, UDSL, Université Lille Nord de France, CHU Lille, France (J.L.).
| |
Collapse
|
21
|
Shimoyama T, Kimura K, Uemura J, Yamashita S, Saji N, Shibazaki K, Iguchi Y. The DASH score: A simple score to assess risk for development of malignant middle cerebral artery infarction. J Neurol Sci 2014; 338:102-6. [DOI: 10.1016/j.jns.2013.12.024] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Revised: 11/26/2013] [Accepted: 12/13/2013] [Indexed: 10/25/2022]
|
22
|
de Margerie-Mellon C, Turc G, Tisserand M, Naggara O, Calvet D, Legrand L, Meder JF, Mas JL, Baron JC, Oppenheim C. Can DWI-ASPECTS Substitute for Lesion Volume in Acute Stroke? Stroke 2013; 44:3565-7. [PMID: 24092549 DOI: 10.1161/strokeaha.113.003047] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
The extent of diffusion lesion on pretreatment imaging is a risk factor for poor outcome and hemorrhagic transformation after thrombolysis, and volumes of 70 to 100 mL have been advocated as cut-offs. However, estimating diffusion-weighted imaging (DWI) lesion volume (Vol
DWI
) in the acute setting may be cumbersome. We aimed to determine whether the DWI-Alberta Stroke Program Early CT Score (DWI-ASPECTS) can substitute for Vol
DWI
.
Methods—
DWI-ASPECTS and Vol
DWI
were measured retrospectively on pretreatment MRI (median onset-to-MRI delay=122 minutes) in 330 consecutively treated patients with middle cerebral artery stroke.
Results—
DWI-ASPECTS and Vol
DWI
were strongly correlated (ρ=−0.82), but each DWI-ASPECTS point corresponded to a wide range of Vol
DWI
. All patients with DWI-ASPECTS ≥7 (n=207) had Vol
DWI
<70 mL, whereas 32 of the 34 patients with DWI-ASPECTS <4 had Vol
DWI
>100 mL. However, intermediate DWI-ASPECTS (4–6; n=89) corresponded to highly variable Vol
DWI
(median, 66 mL; interquartile range, 40–98).
Conclusions—
Although each DWI-ASPECTS point corresponds to a wide range of volumes, DWI-ASPECTS <4 or ≥7 may be used as reliable surrogates of Vol
DWI
>100 or <70 mL, respectively.
Collapse
Affiliation(s)
- Constance de Margerie-Mellon
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Guillaume Turc
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Marie Tisserand
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Olivier Naggara
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - David Calvet
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Laurence Legrand
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Jean-François Meder
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Jean-Louis Mas
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Jean-Claude Baron
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Catherine Oppenheim
- From the Departments of Radiology (C.d.M.-M., M.T., O.N., L.L., J.-F.M., C.O.) and Neurology (G.T., D.C., J.-L.M., J.-C.B.), Centre de Psychiatrie et Neurosciences, INSERM S894, Centre Hospitalier Sainte-Anne, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| |
Collapse
|
23
|
Raoult H, Eugène F, Ferré JC, Gentric JC, Ronzière T, Stamm A, Gauvrit JY. Prognostic factors for outcomes after mechanical thrombectomy with solitaire stent. J Neuroradiol 2013; 40:252-9. [DOI: 10.1016/j.neurad.2013.04.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Revised: 03/27/2013] [Accepted: 04/04/2013] [Indexed: 10/26/2022]
|
24
|
Abstract
Traditionally non-contrast CT has been considered the first choice imaging modality for acute stroke. Acute ischemic stroke patients presenting to the hospital within 3-hours from symptom onset and without any visible hemorrhages or large lesions on CT images are considered optimum reperfusion therapy candidates. However, non-contrast CT alone has been unable to identify best reperfusion therapy candidates outside this window. New advanced imaging techniques are now being used successfully for this purpose. Non-invasive CT or MR angiography images can be obtained during initial imaging evaluation for identification and characterization of vascular lesions, including occlusions, aneurysms, and malformations. Either CT-based perfusion imaging or MRI-based diffusion and perfusion imaging performed immediately upon arrival of a patient to the hospital helps estimate the extent of fixed core and penumbra in ischemic lesions. Patients having occlusive lesions with small fixed cores and large penumbra are preferred reperfusion therapy candidates.
Collapse
|
25
|
Turc G, Apoil M, Naggara O, Calvet D, Lamy C, Tataru AM, Méder JF, Mas JL, Baron JC, Oppenheim C, Touzé E. Magnetic Resonance Imaging-DRAGON Score. Stroke 2013; 44:1323-8. [DOI: 10.1161/strokeaha.111.000127] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
The DRAGON score, which includes clinical and computed tomographic scan parameters, showed a high specificity to predict 3-month outcome in patients with acute ischemic stroke treated by intravenous tissue plasminogen activator. We adapted the score for patients undergoing MRI as the first-line diagnostic tool.
Methods—
We reviewed patients with consecutive anterior circulation ischemic stroke treated ≤4.5 hour by intravenous tissue plasminogen activator between 2003 and 2012 in our center, where MRI is systematically implemented as first-line diagnostic work-up. We derived the MRI-DRAGON score keeping all clinical parameters of computed tomography-DRAGON (age, initial National Institutes of Health Stroke Scale and glucose level, prestroke handicap, onset to treatment time), and considering the following radiological variables: proximal middle cerebral artery occlusion on MR angiography instead of hyperdense middle cerebral artery sign, and diffusion-weighted imaging Alberta Stroke Program Early Computed Tomography Score (DWI ASPECTS) ≤5 instead of early infarct signs on computed tomography. Poor 3-month outcome was defined as modified Rankin scale >2. We calculated c-statistics as a measure of predictive ability and performed an internal cross-validation.
Results—
Two hundred twenty-eight patients were included. Poor outcome was observed in 98 (43%) patients and was significantly associated with all parameters of the MRI-DRAGON score in multivariate analysis, except for onset to treatment time (nonsignificant trend). The c-statistic was 0.83 (95% confidence interval, 0.78–0.88) for poor outcome prediction. All patients with a MRI-DRAGON score ≤2 (n=22) had a good outcome, whereas all patients with a score ≥8 (n=11) had a poor outcome.
Conclusions—
The MRI-DRAGON score is a simple tool to predict 3-month outcome in acute stroke patients screened by MRI then treated by intravenous tissue plasminogen activator and may help for therapeutic decision.
Collapse
Affiliation(s)
- Guillaume Turc
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Marion Apoil
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Olivier Naggara
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - David Calvet
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Catherine Lamy
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Alina M. Tataru
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Jean-François Méder
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Jean-Louis Mas
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Jean-Claude Baron
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Catherine Oppenheim
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| | - Emmanuel Touzé
- From the Service de Neurologie (G.T., M.A., D.C., C.L., A.M.T., J.-L.M., J.-C.B., E.T.) and Service de Neuroradiologie (O.N., J.-F.M., C.O.), Sorbonne Paris Cité, INSERM UMR S894, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; and Service de Neurologie, INSERM U919, GIP Cyceron, CHU Côte de Nacre, Université de Caen Basse Normandie, Caen, France (M.A.)
| |
Collapse
|